Hospital
Rchp-Wilmington, LLC
Rchp-Wilmington, LLC was paid $13.53M by Medicaid between Jan 2018 and Dec 2024, across 231 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoRCHP-WILMINGTON, LLC
WILMINGTON, OH 45177
WILMINGTON, OH 45177
33aNPI1063713659assigned 11/12/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$13.53M
24GClaims439,788
24DCodes billed231
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#65 of 101
Median peer was paid$22.32M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TEAGUE, KATHY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 48,968 | $1.45M | |
| 2019 | 46,421 | $1.31M | |
| 2020 | 37,286 | $1.11M | |
| 2021 | 52,627 | $1.61M | |
| 2022 | 56,220 | $1.83M | |
| 2023 | 130,425 | $3.87M | |
| 2024incomplete | 67,841 | $2.35M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 24,353 | 21,899 | $2.67M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 23,159 | 21,432 | $2.33M |
| 96361 | Intravenous infusion, hydration; each additional hour | 17% | 8,592 | 7,323 | $2.27M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.4% | 9,740 | 8,091 | $1.13M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.5% | 2,229 | 1,887 | $480K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 1,989 | 1,653 | $478K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.6% | 2,554 | 1,654 | $358K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.1% | 4,815 | 2,848 | $287K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 1,053 | 819 | $254K |
| 59025 | Fetal non-stress test | 1.8% | 1,735 | 952 | $245K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.4% | 5,979 | 5,069 | $192K |
| 80053 | Comprehensive metabolic panel | 1.3% | 8,704 | 7,430 | $173K |
219 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 448 | $169K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.2% | 1,383 | $157K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 25,997 | $138K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,136 | $117K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 228 | $112K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 631 | $95K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 665 | $95K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 374 | $92K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,660 | $78K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 33,301 | $76K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,073 | $72K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 162 | $71K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 330 | $71K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 594 | $51K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 584 | $45K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,620 | $44K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,644 | $43K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 738 | $43K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 387 | $40K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 390 | $38K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 597 | $37K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,397 | $36K |
| G0378 | Hospital observation service, per hour | <1% | 962 | $36K |
| 80061 | Lipid panel | <1% | 2,862 | $34K |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 216 | $31K |
| 80076 | <1% | 11,522 | $30K | |
| 84484 | <1% | 8,389 | $29K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,103 | $28K |
| 86592 | <1% | 987 | $27K | |
| 86900 | <1% | 1,141 | $26K | |
| 80069 | <1% | 1,644 | $26K | |
| 83970 | <1% | 1,264 | $25K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,150 | $24K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,107 | $24K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,857 | $23K |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,587 | $23K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,185 | $22K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 71 | $22K |
| 87806 | <1% | 461 | $20K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 521 | $18K |
| 82607 | <1% | 1,102 | $16K | |
| 86850 | <1% | 1,000 | $12K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 112 | $12K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,829 | $12K |
| 72110 | <1% | 280 | $12K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 181 | $11K |
| 82728 | <1% | 740 | $11K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,297 | $11K |
| 74018 | <1% | 451 | $11K | |
| 71250 | <1% | 132 | $11K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 519 | $11K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,103 | $10K |
| 86803 | <1% | 516 | $10K | |
| J3490 | Unclassified drugs | <1% | 840 | $10K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 576 | $9K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 249 | $9K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 76 | $9K |
| 84439 | <1% | 748 | $9K | |
| 93017 | <1% | 119 | $8K | |
| 86901 | <1% | 1,141 | $8K | |
| 76775 | <1% | 74 | $8K | |
| 87340 | <1% | 519 | $8K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 415 | $8K |
| 82746 | <1% | 827 | $7K | |
| 83550 | <1% | 770 | $7K | |
| 72131 | <1% | 122 | $7K | |
| 84702 | <1% | 740 | $7K | |
| 84550 | <1% | 1,476 | $7K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,118 | $6K |
| 83540 | <1% | 787 | $6K | |
| 93976 | <1% | 83 | $6K | |
| 97161 | <1% | 161 | $6K | |
| 87081 | <1% | 947 | $6K | |
| 73030 | <1% | 303 | $6K | |
| 73630 | <1% | 607 | $6K | |
| 85027 | <1% | 1,432 | $5K | |
| 81001 | <1% | 11,276 | $5K | |
| 85014 | <1% | 917 | $5K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 25 | $5K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 28 | $5K |
| 93971 | <1% | 46 | $5K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 9,781 | $5K |
| 86762 | <1% | 298 | $4K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,573 | $4K |
| 82950 | <1% | 332 | $4K | |
| 76642 | <1% | 36 | $4K | |
| 96367 | <1% | 38 | $4K | |
| 73610 | <1% | 337 | $4K | |
| 90715 | <1% | 250 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 7,854 | $4K |
| 85018 | <1% | 1,491 | $3K | |
| 83735 | <1% | 1,069 | $3K | |
| 85610 | <1% | 2,894 | $3K | |
| 73130 | <1% | 319 | $3K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 14 | $3K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 18 | $3K |
| 84153 | <1% | 183 | $3K | |
| 76536 | <1% | 28 | $3K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 16 | $3K |
| 93356 | <1% | 12 | $3K | |
| 73502 | <1% | 120 | $3K | |
| 71271 | <1% | 14 | $3K | |
| 12001 | <1% | 20 | $2K | |
| 82962 | <1% | 2,131 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,124 | $2K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $2K |
| 83690 | <1% | 7,948 | $2K | |
| 81003 | <1% | 4,976 | $2K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $2K |
| 82565 | <1% | 309 | $2K | |
| 86880 | <1% | 149 | $2K | |
| 83605 | <1% | 1,538 | $2K | |
| 83880 | <1% | 1,010 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,850 | $2K |
| 88142 | <1% | 78 | $1K | |
| 70486 | <1% | 15 | $1K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,854 | $1K |
| 83525 | <1% | 55 | $1K | |
| 96376 | <1% | 889 | $1K | |
| 85379 | <1% | 1,571 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,632 | $1K |
| 85730 | <1% | 2,264 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 965 | $1K |
| 94664 | <1% | 218 | $1K | |
| 82043 | <1% | 159 | $1K | |
| 86140 | <1% | 88 | $1K | |
| 81025 | <1% | 5,417 | $1K | |
| 87040 | <1% | 737 | $1K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 58 | $1K |
| 73110 | <1% | 58 | $1K | |
| 82570 | <1% | 327 | $994.98 | |
| 87186 | <1% | 941 | $986.21 | |
| 82784 | <1% | 59 | $982.14 | |
| 74420 | <1% | 15 | $963.32 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,725 | $897.09 |
| 83615 | <1% | 339 | $884.11 | |
| 87070 | <1% | 1,241 | $757.43 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 32 | $755.61 |
| 76801 | <1% | 13 | $738.33 | |
| 82150 | <1% | 1,175 | $730.26 | |
| 84156 | <1% | 335 | $729.62 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 13 | $676.68 |
| 84100 | <1% | 183 | $637.12 | |
| 82803 | <1% | 404 | $598.05 | |
| 84403 | <1% | 18 | $578.17 | |
| 82105 | <1% | 19 | $466.40 | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 38 | $463.57 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,053 | $438.17 |
| 36591 | <1% | 463 | $421.13 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 17 | $418.97 |
| 87280 | <1% | 588 | $399.63 | |
| 86706 | <1% | 28 | $394.51 | |
| 85651 | <1% | 71 | $383.60 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,798 | $379.39 |
| 73560 | <1% | 193 | $361.28 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 16 | $350.68 |
| 00731 | <1% | 51 | $328.72 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 944 | $322.14 |
| 83516 | <1% | 14 | $322.10 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,879 | $313.74 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,228 | $306.50 |
| 73590 | <1% | 34 | $302.02 | |
| 97597 | <1% | 36 | $292.52 | |
| 87077 | <1% | 726 | $281.83 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 735 | $233.60 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 930 | $206.87 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,131 | $175.61 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,338 | $167.72 |
| 85007 | <1% | 144 | $162.09 | |
| 87088 | <1% | 35 | $148.28 | |
| 86704 | <1% | 12 | $134.44 | |
| 82947 | <1% | 14 | $129.13 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 523 | $124.12 |
| 94762 | <1% | 879 | $121.55 | |
| 87205 | <1% | 1,019 | $106.75 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,727 | $76.65 |
| 88304 | <1% | 64 | $74.71 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 50 | $67.59 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 140 | $66.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 50 | $61.75 |
| 84145 | <1% | 115 | $58.73 | |
| 85652 | <1% | 12 | $54.31 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 137 | $52.11 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 905 | $46.40 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 281 | $40.01 |
| 0012A | <1% | 25 | $37.98 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 854 | $35.04 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 375 | $33.42 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 394 | $31.79 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 19 | $29.34 |
| 82010 | <1% | 101 | $29.26 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 329 | $22.74 |
| 80329 | <1% | 13 | $22.48 | |
| 80348 | <1% | 158 | $17.13 | |
| 82247 | <1% | 23 | $16.63 | |
| 84703 | <1% | 13 | $14.88 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,141 | $11.72 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 184 | $10.61 |
| J2704 | Injection, propofol, 10 mg | <1% | 329 | $9.36 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 45 | $7.15 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 20 | $6.30 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 252 | $3.95 |
| C1769 | Guide wire | 0% | 278 | $0.00 |
| 94760 | 0% | 4,339 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 80 | $0.00 |
| 91301 | 0% | 54 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 18 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 75 | $0.00 |
| 88342 | 0% | 19 | $0.00 | |
| 0011A | 0% | 32 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 32 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 390 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 51 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 21 | $0.00 |
| 84450 | 0% | 22 | $0.00 | |
| 00812 | 0% | 13 | $0.00 | |
| 84460 | 0% | 22 | $0.00 | |
| 80305 | 0% | 27 | $0.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTEAGUE, KATHY (VICE PRESIDENT, CORPORATE SECRETARY)
| Provider | Location | Paid |
|---|---|---|
| Providence Hospital, LLC | Columbia, SC | $12.68M |
| Vaughan Regional Medical Center LLC | Selma, AL | $8.15M |
| Kershaw Hospital LLC | Camden, SC | $7.93M |
| Bolivar Physician Practices LLC | Cleveland, MS | $3.05M |
| Wilmington Physicians Group LLC | Wilmington, OH | $3.04M |
| Phc-Morgan City LP | Morgan City, LA | $2.37M |
| Community Hospital of Andalusia LLC | Andalusia, AL | $2.27M |
| Vaughan Regional Medical Center LLC | Marion, AL | $2.15M |
| PRHC Ennis LP | Ennis, TX | $1.81M |
| Andalusia Physician Practices LLC | Andalusia, AL | $847K |
| Meadowview Physician Practice LLC | Maysville, KY | $783K |
| Logan Physician Practice LLC | Auburn, KY | $458K |
| Logan Physician Practice LLC | Russellville, KY | $317K |
| Kentucky Mso LLC | Georgetown, KY | $248K |
| Rchp-Wilmington, LLC | Wilmington, OH | $165K |
| Meadowview Physician Practice LLC | Maysville, KY | $140K |
| Amg-Southern Tennessee LLC | Monteagle, TN | $136K |
| Lake Cumberland Physician Practices LLC | Somerset, KY | $135K |
| Lake Cumberland Physician Practices LLC | Somerset, KY | $57K |
| Kershaw Hospital LLC | Lugoff, SC | $49K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.